Evidence map›Paper›PMID 12117990›Full record

ArticleInfection and immunity2002

CD40 ligand (CD154) does not contribute to lymphocyte-mediated inhibition of virulent Mycobacterium tuberculosis within human monocytes.

Rhonda Larkin, Christopher D Benjamin, Yen-Ming Hsu, Qing Li, Lynn Zukowski, Richard F Silver

Open access · greenAbstract read
In one paragraph

Article in Infection and immunity, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Rhonda LarkinDivision of Pulmonary and Critical Care Medicine, Case Western Reserve University School of Medicine, Ohio 44106-4984, USA.
Christopher D Benjamin
Yen-Ming Hsu
Qing Li
Lynn Zukowski
Richard F Silver
Pulmonary and Critical Care Associates · USBiogen (United States) · US

Funding

WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Mark James Cameron · 1994 to 2026
$50.0M
CONTACT-MEDIATED HOST RESISTANCE TO M TUBERCULOSISR01HL059858 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI SILVER, RICHARD F · 1997 to 2001
$459k
SECOND-GENERATION VACCINES AGAINST LYME DISEASER01AI035027 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI PHILIPP, MARIO TOMAS · 1994 to 1996
–
SECOND GENERATION VACCINES AGAINST LYME DISEASER21AI035027 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI PHILIPP, MARIO TOMAS · 1998 to 1998
–
NHLBI NIH HHS HL59858NIAID NIH HHS AI 35027NIAID NIH HHS P30 AI036219
6 · The paper itself

Abstract

Human monocytes displayed increased expression of CD40 following infection with virulent Mycobacterium tuberculosis. Nevertheless, soluble CD40 ligand (CD40L; also designated CD154) had no effect on the intracellular growth of the organism. Restriction of the intracellular growth of M. tuberculosis by peripheral blood lymphocytes and antigen-specific CD4+ T-cell lines likewise was not reduced by blocking anti-CD40L monoclonal antibody 5c8.

Indexed as

AdultAntibodies, MonoclonalCD40 AntigensCD40 LigandCD4-Positive T-LymphocytesCell LineHumansIntracellular FluidLymphocytesMiddle AgedMonocytesMycobacterium tuberculosisRecombinant ProteinsVirulenceAntibodies, MonoclonalCD40 AntigensCD40 LigandRecombinant Proteins

Identifiers

PMID12117990
PMCPMC128186
OpenAlexW2165052236

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.